Seres Therapeutics Inc (MCRB)’s financial ratios: A comprehensive overview

The closing price of Seres Therapeutics Inc (NASDAQ: MCRB) was $1.20 for the day, up 2.56% from the previous closing price of $1.17. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 2823197 shares were traded.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Ratios:

Our analysis of MCRB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 2.71.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 30 when Shaff Eric D. sold 8,552 shares for $1.35 per share. The transaction valued at 11,545 led to the insider holds 115,620 shares of the business.

von Moltke Lisa sold 4,232 shares of MCRB for $5,713 on Oct 30. The insider now owns 9,513 shares after completing the transaction at $1.35 per share. On Oct 30, another insider, DesRosier Thomas, who serves as the Chief Legal Officer and EVP of the company, sold 4,156 shares for $1.35 each. As a result, the insider received 5,611 and left with 113,891 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 155.11M and an Enterprise Value of 197.47M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.22. Its current Enterprise Value per Revenue stands at 1.55 whereas that against EBITDA is -1.59.

Stock Price History:

Over the past 52 weeks, MCRB has reached a high of $6.87, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 1.1783, while the 200-Day Moving Average is calculated to be 3.4457.

Shares Statistics:

MCRB traded an average of 5.18M shares per day over the past three months and 8.29M shares per day over the past ten days. A total of 125.22M shares are outstanding, with a floating share count of 97.45M. Insiders hold about 24.61% of the company’s shares, while institutions hold 65.34% stake in the company. Shares short for MCRB as of Dec 28, 2023 were 16.28M with a Short Ratio of 16.28M, compared to 20.95M on Nov 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.59% and a Short% of Float of 23.68%.

Earnings Estimates

The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.49 for the current quarter, with a high estimate of -$0.32 and a low estimate of -$1, while EPS last year was -$0.54. The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.28 and low estimates of -$0.42.

Analysts are recommending an EPS of between -$0.89 and -$1.07 for the fiscal current year, implying an average EPS of -$0.98. EPS for the following year is -$1.36, with 7 analysts recommending between -$0.85 and -$2.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for MCRB’s current fiscal year. The highest revenue estimate was $127.8M, while the lowest revenue estimate was $123.08M, resulting in an average revenue estimate of $126.07M. In the same quarter a year ago, actual revenue was $7.13M, up 1,668.70% from the average estimate.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular